JP7653408B2 - 抗ｐｄ－ｌ１抗体 - Google Patents

抗ｐｄ－ｌ１抗体 Download PDF

Info

Publication number
JP7653408B2
JP7653408B2 JP2022502425A JP2022502425A JP7653408B2 JP 7653408 B2 JP7653408 B2 JP 7653408B2 JP 2022502425 A JP2022502425 A JP 2022502425A JP 2022502425 A JP2022502425 A JP 2022502425A JP 7653408 B2 JP7653408 B2 JP 7653408B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antigen
acid sequence
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541192A5 (https=
JP2022541192A (ja
Inventor
スティーヴ ホームズ
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2022541192A publication Critical patent/JP2022541192A/ja
Publication of JP2022541192A5 publication Critical patent/JP2022541192A5/ja
Application granted granted Critical
Publication of JP7653408B2 publication Critical patent/JP7653408B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022502425A 2019-07-15 2020-07-15 抗ｐｄ－ｌ１抗体 Active JP7653408B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1910138.5 2019-07-15
GBGB1910138.5A GB201910138D0 (en) 2019-07-15 2019-07-15 Anti-pd-l1 antibodies
PCT/EP2020/070065 WO2021009267A1 (en) 2019-07-15 2020-07-15 Anti-pd-l1 antibodies

Publications (3)

Publication Number Publication Date
JP2022541192A JP2022541192A (ja) 2022-09-22
JP2022541192A5 JP2022541192A5 (https=) 2023-07-18
JP7653408B2 true JP7653408B2 (ja) 2025-03-28

Family

ID=67700332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502425A Active JP7653408B2 (ja) 2019-07-15 2020-07-15 抗ｐｄ－ｌ１抗体

Country Status (8)

Country Link
US (1) US20220356255A1 (https=)
EP (1) EP3999113A1 (https=)
JP (1) JP7653408B2 (https=)
KR (1) KR20220057526A (https=)
CN (1) CN114829400B (https=)
CA (1) CA3143957A1 (https=)
GB (1) GB201910138D0 (https=)
WO (1) WO2021009267A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023016706A2 (pt) * 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
CN116917322A (zh) * 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544755A (ja) 2005-07-01 2008-12-11 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
JP2013511959A (ja) 2009-11-24 2013-04-11 メディミューン リミテッド Ｂ７−ｈ１に対する標的結合剤
JP2015500207A (ja) 2011-11-28 2015-01-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテ 抗ｐｄ−ｌ１抗体及びその使用
JP2015535691A (ja) 2012-10-04 2015-12-17 デイナ ファーバー キャンサー インスティチュート，イ ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
JP2017507650A (ja) 2014-01-23 2017-03-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｄ−ｌ１に対するヒト抗体
JP2019503687A (ja) 2016-01-04 2019-02-14 ジアンスー ヒャマブ ファーマシューティカル カンパニー リミテッド 抗ｐｄ−ｌ１抗体およびその使用
JP2019516394A (ja) 2016-03-23 2019-06-20 マブスペース バイオサイエンシズ （スーチョウ） カンパニー，リミテッド 新規抗ｐｄ−ｌ１抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN108948193B (zh) * 2017-05-18 2022-12-09 上海健信生物医药科技有限公司 针对tim-3的抗体分子,抗原结合片段及其医药用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544755A (ja) 2005-07-01 2008-12-11 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
JP2013511959A (ja) 2009-11-24 2013-04-11 メディミューン リミテッド Ｂ７−ｈ１に対する標的結合剤
JP2015500207A (ja) 2011-11-28 2015-01-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテ 抗ｐｄ−ｌ１抗体及びその使用
JP2015535691A (ja) 2012-10-04 2015-12-17 デイナ ファーバー キャンサー インスティチュート，イ ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
JP2017507650A (ja) 2014-01-23 2017-03-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｄ−ｌ１に対するヒト抗体
JP2019503687A (ja) 2016-01-04 2019-02-14 ジアンスー ヒャマブ ファーマシューティカル カンパニー リミテッド 抗ｐｄ−ｌ１抗体およびその使用
JP2019516394A (ja) 2016-03-23 2019-06-20 マブスペース バイオサイエンシズ （スーチョウ） カンパニー，リミテッド 新規抗ｐｄ−ｌ１抗体

Also Published As

Publication number Publication date
GB201910138D0 (en) 2019-08-28
CA3143957A1 (en) 2021-01-21
KR20220057526A (ko) 2022-05-09
EP3999113A1 (en) 2022-05-25
CN114829400A (zh) 2022-07-29
US20220356255A1 (en) 2022-11-10
WO2021009267A1 (en) 2021-01-21
CN114829400B (zh) 2024-05-17
JP2022541192A (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
AU2021405058A1 (en) Multispecific antibodies having specificity for il-4r and il-31
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
JP2022084832A (ja) ヒト化抗ベイシジン抗体およびその使用
US20240309087A1 (en) Anti-cd112r antibody and use thereof
US20240294655A1 (en) Antigen binding molecules that bind light
WO2021063352A1 (zh) 一种抗pd-l1抗原结合蛋白及其应用
CA3189473A1 (en) Novel human antibodies binding to human cd3 epsilon
TW202202529A (zh) 一種雙特異性抗體及其用途
CN108948193B (zh) 针对tim-3的抗体分子,抗原结合片段及其医药用途
TW201922798A (zh) 靶向rankl的治療性抗體
CN117355540A (zh) 抗cd137抗体和使用方法
JP7653408B2 (ja) 抗ｐｄ－ｌ１抗体
KR20210016056A (ko) 항-bcma 항체 및 그 용도
WO2025162161A1 (zh) 特异性结合pd-1的单克隆抗体及其医药用途
JP2025526279A (ja) 抗ＴＮＦα抗体および組成物
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
TWI843182B (zh) 一種抗b7-h4抗體及其製備方法和應用
US20250154242A1 (en) Anti-tnf-alpha antibodies and compositions
WO2025163564A1 (en) Antigen binding molecules that bind bdca-2
JP2025539145A (ja) 抗ｃｄ１３７抗体及びその使用方法
WO2025228298A1 (zh) 靶向TROP2xPD-L1的双特异性抗体药物偶联物及其制备方法与应用
TW202430556A (zh) 治療癌症患者之pd-1拮抗劑、tigit拮抗劑及結合191p4d12蛋白之抗體藥物結合物之組合療法
JP2026503602A (ja) Ｎｋｇ２ａ及びｐｄ－ｌ１に結合する薬剤、及びその使用
WO2022012639A1 (zh) Pd-1抗原结合蛋白及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220307

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240308

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240621

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250317

R150 Certificate of patent or registration of utility model

Ref document number: 7653408

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150